## GERRESHEIMER

**Analyst / Investor Conference Call** 

Results Q2 2014

Uwe Röhrhoff, Chief Executive Officer

Rainer Beaujean, Chief Financial Officer

July 10, 2014 // 03:00 p.m. CEST

# GERRESHEIMER



...our most comprehensive product portfolio



#### **Disclaimer**

- This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein.
- The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast development.
- No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.



#### **Agenda**

■ Review Q2 2014

Uwe Röhrhoff, CEO

■ Financial Overview Q2 2014

Rainer Beaujean, CFO


■ Guidance FY 2014

Uwe Röhrhoff, CEO

Appendix



#### Q2 2014: Strong development of operating metrics





#### Q2 2014: Revenue and margin growth driven by all divisions

#### ■ Plastics & Devices:

- Strong organic growth driven by primary packaging, tooling and syringes business
- Adjusted EBITDA margin increased slightly

#### Primary Packaging Glass:

- Normalized demand situation led to growth in the quarter
- Adjusted EBITDA margin markedly up

#### ■ Life Science Research:

- ➤ Demand stabilized, revenues at constant currencies up on prior year's quarter
- Solid demand and strict cost management led to strong adjusted EBITDA margin



#### **Agenda**

Review Q2 2014

Uwe Röhrhoff, CEO

■ Financial Overview Q2 2014

Rainer Beaujean, CFO

■ Guidance FY 2014

Uwe Röhrhoff, CEO

Appendix



### Q2 2014: Revenues by division

	Q2 2014 EUR m	Q2 2013 EUR m	Change in %	Change in % at const. FX¹
Total Group	335.4	327.1	+2.6	+6.0
Plastics & Devices	160.2	150.5	+6.4	+10.6
Primary Packaging Glass	158.0	159.0	-0.6	+2.1
Life Science Research	21.7	22.4	-2.6	+2.8

<sup>&</sup>lt;sup>1</sup> Currency effects are generally translation effects



#### Q2 2014: Adjusted EBITDA<sup>1</sup> and margin by division

	Q2 2014		Q2 2013	
	EUR m	Margin in %	EUR m	Margin in %
Total Group	65.1	19.4	59.8	18.3
Plastics & Devices	33.0	20.6	30.9	20.5
Primary Packaging Glass	33.7	21.3	31.3	19.7
Life Science Research	3.0	14.0	3.0	13.4

<sup>&</sup>lt;sup>1</sup> Earnings before income taxes, net finance expense, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses



#### Key balance sheet and cash flow figures

	May 31, 2014 EUR m	May 31, 2013 EUR m	Change in %
Total assets	1,632.6	1,664.8	-0.7
Equity Equity ratio in %	570.6 35.0	535.2 32.1	+6.6
Net working capital <sup>1</sup> in % of LTM revenues	239.8 <i>18.8</i>	222.0 17.6	+8.0
	Q2 2014 EUR m	Q2 2013 EUR m	Change in %
Capex	25.1	33.4	-24.9
Cash flow from op. activities	15.8	30.8	-48.6

<sup>&</sup>lt;sup>1</sup> Inventories (incl. prepayments made) and trade receivables less trade payables and payments received on account of orders



### Long-term financing structure with ample financial leeway

Debt/cash positions in EUR m	May 31, 2014 EUR m	May 31, 2013 EUR m	Change in %
Bond	300.0	300.0	-
Long-term bank debt	83.9	111.7	-24.9
Revolving bank debt	150.1	123.9	+21.1
Local borrowings and leasing	14.5	14.9	-2.7
Total financial debt	548.5	550.5	-0.4
./. Cash and cash equivalents	79.5	93.0	-14.5
Net financial debt	469.0	457.5	+2.5
Adjusted LTM EBITDA	256.7	241.1 <sup>1</sup>	+6.5
Adjusted EBITDA leverage	1.8	1.9 <sup>1</sup>	-5.3

 $<sup>^{\</sup>rm 1}$  Retrospective restatement due to the early adoption of IAS 19 (amended in 2011) from December 1, 2012



#### **Agenda**

Review Q2 2014

Uwe Röhrhoff, CEO

■ Financial Overview Q2 2014


Rainer Beaujean, CFO

■ Guidance FY 2014

Uwe Röhrhoff, CEO

Appendix







#### **Financial Calendar**

October 8, 2014

Interim Report 3rd Quarter 2014

October 8+9, 2014

Capital Markets Day 2014



#### **Investor Relations & Creditor Relations contact details**

**Phone** +49 211 6181-257

**Fax** +49 211 6181-121

**E-mail** gerresheimer.ir@gerresheimer.com

IR website www.gerresheimer.com/ir



#### **Agenda**

Review Q2 2014

Uwe Röhrhoff, CEO

■ Financial Overview Q2 2014

Rainer Beaujean, CFO

■ Guidance FY 2014

Uwe Röhrhoff, CEO

**■** Appendix

## GERRESHEIMER

#### Gerresheimer: Divisional setup effective from Dec 1, 2013

#### **Customer-focused organization with 3 divisions**













Life Science Research Rainer Beaujean



#### Q2 2014 P&L overview

	Q2 2014 EUR m	Q2 2013 EUR m	Change in %
Revenues	335.4	327.1	+2.6
Adjusted EBITDA <sup>1</sup>	65.1	59.8	+9.1
One-off income/expense	-0.3	-0.1	>-100
EBITDA	64.8	59.7	+8.5
Amortization of FV adjustments	5.2	5.5	-5.5
Depreciation and amortization	21.8	20.6	+5.8
Profit before interest and taxes (EBIT)	37.8	33.6	+12.7
Net finance expense	7.3	9.2	-20.7
Profit before taxes	30.5	24.4	+25.0
Income taxes	-9.7	-12.1	+19.8
Net income	20.8	12.3	+70.3
EPS in EUR	0.61	0.34	+79.4
Adjusted EPS in EUR <sup>2</sup>	0.73	0.63	+15.9

<sup>&</sup>lt;sup>1</sup> Earnings before income taxes, net finance expense, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses
<sup>2</sup> Adjusted net income after non-controlling interests divided by 31.4m shares



#### Development of working capital<sup>1</sup>

	May 31, 2014 EUR m	May 31, 2013 EUR m	Nov 30, 2013 EUR m
Inventories  thereof prepayments	199.5	203.0	194.5
made	15.9	19.3	14.0
Trade receivables	189.8	192.1	192.6
Trade payables	104.2	130.9	127.0
Payments received on account of orders	45.3	42.2	58.2
Net working capital in % of LTM revenues	239.8 18.8	222.0 17.6	201.9 <i>15</i> .9

<sup>&</sup>lt;sup>1</sup> Inventories (incl. prepayments made) and trade receivables less trade payables and payments received on account of orders



## **Development of inventories**

	May 31, 2014 EUR m	May 31, 2013 EUR m	Nov 30, 2013 EUR m
Raw materials, consumables and supplies	52.8	50.4	48.8
Work in progress	24.5	19.0	33.1
Finished goods and merchandise	106.3	114.3	98.6
Prepayments made	15.9	19.3	14.0
Inventories	199.5	203.0	194.5



#### Q1-Q2 2014: Revenues by division

	Q1-Q2 2014 EUR m	Q1-Q2 2013 EUR m	Change in %	Change in % at const. FX <sup>1</sup>
Total Group	632.9	623.8	+1.5	+4.6
Plastics & Devices	295.8	280.8	+5.3	+9.4
Primary Packaging Glass	304.0	308.0	-1.3	+1.0
Life Science Research	42.0	43.9	-4.2	-

<sup>&</sup>lt;sup>1</sup> Currency effects are generally translation effects



## Q1-Q2 2014: Adjusted EBITDA<sup>1</sup> and margin by division

	Q1-Q2 2014		Q1-Q2 2013	
	EUR m	Margin in %	EUR m	Margin in %
Total Group	112.7	17.8	105.8	17.0
Plastics & Devices	54.0	18.3	50.8	18.1
Primary Packaging Glass	62.4	20.5	60.4	19.6
Life Science Research	5.5	13.1	5.5	12.5

<sup>&</sup>lt;sup>1</sup> Earnings before income taxes, net finance expense, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses



#### **Q1-Q2 2014 P&L overview**

	Q1-Q2 2014 EUR m	Q1-Q2 2013 EUR m	Change in %
Revenues	632.9	623.8	+1.5
Adjusted EBITDA <sup>1</sup>	112.7	105.8	+6.6
One-off income/expense	-0.3	-0.2	-50.0
EBITDA	112.4	105.6	+6.4
Amortization of FV adjustments	9.4	9.3	+1.1
Depreciation and amortization	43.5	41.2	+5.6
Profit before interest and taxes (EBIT)	59.5	55.1	+8.1
Net finance expense	14.8	15.6	-5.1
Profit before taxes	44.7	39.5	+13.2
Income taxes	-13.6	-17.0	+20.0
Net income	31.1	22.5	+38.6
EPS in EUR	0.90	0.62	+45.2
Adjusted EPS in EUR <sup>2</sup>	1.11	0.99	+12.1

<sup>&</sup>lt;sup>1</sup> Earnings before income taxes, net finance expense, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses <sup>2</sup> Adjusted net income after non-controlling interests divided by 31.4m shares